Continual spontaneous urticaria (CSU, “continual hives”) might be maddening: day by day itch, unpredictable wheals, and flares that don’t reply to antihistamines. Over the previous few years clinicians have gained new focused choices past antihistamines — an injectable anti-IgE (Xolair), an injectable IL-4/13 blocker (Dupixent), and most just lately an oral BTK inhibitor (Rhapsido/remibrutinib). Under I evaluate how they work, the proof, sensible variations (route, dosing, onset), security and entry that can assist you perceive the panorama earlier than discussing decisions together with your clinician.
-
Rhapsido (remibrutinib) — oral BTK inhibitor; FDA authorised Oct 2025 for adults with CSU not managed on H1 antihistamines; capsule, twice day by day; fast onset reported in trials.
-
Xolair (omalizumab) — anti-IgE monoclonal antibody; established second-line for CSU (subcutaneous injection each 4 weeks; 150 mg or 300 mg). Lengthy real-world expertise.
-
Dupixent (dupilumab) — IL-4/IL-13 pathway blocker; authorised for CSU in 2025 for sufferers remaining symptomatic regardless of antihistamines; subcutaneous injection (loading dose then q2w).
-
Rhapsido (remibrutinib) blocks Bruton’s tyrosine kinase (BTK) inside mast cells and different immune cells — this reduces launch of histamine and pro-inflammatory mediators, and is a small-molecule (oral) method moderately than an antibody.Rhapsido (remibrutinib) wins FDA approval for continual hives
-
Xolair (omalizumab) is an anti-IgE antibody that neutralizes free IgE and downregulates high-affinity IgE receptors on mast cells and basophils, decreasing their activation. Xolair Therapy Period for Hives
-
Dupixent (dupilumab) blocks IL-4 and IL-13 signaling (key type-2 cytokines), modulating downstream inflammatory pathways implicated in some sufferers with CSU. Dupixent for Hives
-
Xolair has the longest observe document in CSU with a number of randomized trials and real-world expertise exhibiting significant reductions in itch and hive counts; it’s the established biologic many tips reference. FDA Entry Information
-
Dupixent was granted approval for CSU after current trials confirmed profit for sufferers nonetheless symptomatic on antihistamines; it’s now an authorised different for eligible sufferers.
-
Rhapsido’s Part 3 information confirmed fast symptom enchancment (some sufferers bettering inside ~2 weeks) and a subset changing into symptom-free; its approval introduces the primary oral focused BTK choice for CSU.
A current comparative/meta-analytic work (and knowledgeable opinions) suggests variations in magnitude and velocity of response throughout brokers — some analyses point out omalizumab typically exhibits the most important general impact dimension at frequent trial endpoints, however community meta-analyses proceed to evolve as new information (e.g., remibrutinib trials, dupilumab trials) accumulate. Particular person response varies — some sufferers who fail one biologic reply to a different.
-
Rhapsido: oral capsule (handy for individuals who dislike injections). Label and press supplies describe twice-daily dosing with no routine lab monitoring required in trials. Novartis
-
Xolair: subcutaneous injection each 4 weeks (150 mg or 300 mg relying on response); might be administered in clinic or at dwelling relying on insurance coverage/applications.
-
Dupixent: subcutaneous injection with an preliminary loading dose (600 mg) then 300 mg each 2 weeks for adults with CSU (per label); self-injectable after coaching is frequent. Regeneron
Onset: Rhapsido trials reported symptom reductions as shortly as ~2 weeks in lots of sufferers; Xolair typically exhibits enchancment inside 2–4 weeks for responders; Dupixent responses differ however significant profit in trials occurred over weeks. Particular person timing varies.
-
Rhapsido (oral BTK inhibitor): trial security profiles famous tolerability with no routine lab monitoring required per the label/press supplies; as with every newer agent, longer-term security in broader populations will proceed to be characterised. Novartis
-
Xolair: lengthy security document — principal considerations embrace injection-site reactions and uncommon reviews of anaphylaxis (therefore preliminary injections are sometimes supervised). No routine lab monitoring is required. FDA Entry Information
-
Dupixent: usually effectively tolerated; frequent hostile occasions embrace injection-site reactions and conjunctivitis in some sufferers; severe hostile occasions are unusual however monitoring and scientific judgement are essential. Regeneron
All the time focus on particular person dangers (comorbidities, being pregnant, an infection threat, drug interactions) together with your prescribing clinician.
-
Rhapsido was launched with a reported wholesale acquisition value of roughly $4,500 per 30-day provide (US), although precise affected person out-of-pocket depends upon insurance coverage, copay help, and producer applications.
-
Xolair and Dupixent are additionally high-cost specialty drugs however have intensive insurance coverage pathways and affected person help applications; protection selections differ by insurer and prior-authorization standards. Producer co-pay help or specialty pharmacy help can change the affected person value considerably.
-
Desire Xolair while you need the best-studied biologic with lengthy expertise in CSU, particularly when prior tips or payer insurance policies favor anti-IgE remedy. FDA Entry Information
-
Contemplate Dupixent for sufferers who stay symptomatic on antihistamines and both can’t use or didn’t reply to Xolair — now an authorised different choice.
-
Contemplate Rhapsido for sufferers preferring an oral therapy (capsule) over injections, or for many who haven’t responded to or can not entry biologics — it’s a brand new, completely different mechanism (BTK inhibition) and confirmed comparatively fast onset in trials. Insurance coverage protection patterns could lag for a brand new drug, so prior authorization and value discussions are key.
As a result of particular person response is unpredictable, switching between mechanisms (anti-IgE → IL-4/13 blocker → BTK inhibitor, or vice versa) is usually efficient — work carefully with an allergist/dermatologist to sequence remedy and monitor response.
All three brokers — Rhapsido (remibrutinib), Xolair (omalizumab) and Dupixent (dupilumab) — broaden choices for sufferers with continual spontaneous urticaria who don’t get aid from antihistamines. They differ in mechanism (BTK vs IgE vs IL-4/13), route (oral vs injectable), dosing frequency, proof base and value/entry. Xolair is the longest-used choice with a deep proof base; Dupixent is an authorised biologic different; Rhapsido brings a handy oral choice and fast results in trials. Your best option depends upon prior therapy historical past, comorbidities, route desire, insurance coverage protection, and the way shortly you want symptom management.
